IVD Giant Hologic Goes Private as Longtime CEO Stephen P. MacMillan Retires Following $18.3B Blackstone-TPG Buyout

On the surface, this is an ordinary piece of personnel news. However, when viewed against the current industry backdrop, its significance goes far beyond that.

One key point must be clarified first: This is not a traditional "CEO resignation."

MacMillan's retirement is conditional — it will take effect after the company is acquired by Blackstone and TPG.

In other words, this represents a complete logical chain: privatization → governance restructuring → management turnover, which is actually a very mature path in the global medical device industry.

When a company switches from being a "publicly listed company" to a "platform controlled by private equity capital," it no longer requires the same type of management.

In other words: This is not a departure, but a mission accomplished.

If we look back, the Q1 2026 financial report has actually already given signals.

Overall, this is a "fairly good" report card: revenue of $1.048 billion, a year-over-year increase of 2.5%; Non-GAAP EPS growth of 1.0%.

But if we delve deeper, it's a completely different story. Diagnostic operations started to face pressure: diagnostic revenue decreased by 1.3% year-over-year, and molecular diagnostics revenue dropped by 3.5%.

The reason is not complicated: after the end of the COVID pandemic, the demand for COVID testing plummeted, coupled with weak demand for some traditional testing items. This is not Hologic's problem; it is an issue for the entire IVD industry.

But more crucially, on the other hand: gynecological surgery operations grew by 8.7%, and breast health operations increased by 1.8%. What does this indicate? Growth is shifting from "detection" towards "treatment and intervention."

If you only look at the data, you might think: this is just a company transitioning from high growth to stable growth.

But the truly important change is something else —Companies begin to operate no longer according to the logic of the capital market.

In the financial report, there is a very crucial sentence:The company will no longer provide annual or quarterly earnings guidance.What does this mean?

Means —— Hologic no longer needs to "explain itself to the market every quarter."

And once free from such constraints, the decision-making logic of enterprises will change completely.

If we zoom out on this issue, a clearer trend emerges: what Hologic is experiencing is not an isolated case, but a microcosm of the entire IVD industry.

You can compare several companies: Roche's operations in China are under pressure, with its core laboratory business impacted by policy changes; Danaher continues to strengthen its moat through acquisitions and platform integration; Mindray is transitioning from a device company to a platform-based enterprise.

You will discover a common trend: the industry is transitioning from "product competition" to "system competition."

And behind this are three things happening at the same time: First, changes on the demand side, the incremental boost driven by the pandemic has disappeared, and the market has returned to normal; Second, tightening on the payment side, with cost control in healthcare continuously strengthening globally; Third, the reconfiguration of technology and scenarios, where AI, automation, and systematic capabilities have become the new core of competition.

When the three variables of demand, payment, and technology converge simultaneously, a new industry cycle has quietly begun.

This is not a simple fluctuation, but a structural reconstruction — the old growth logic is fading, and a new competitive order is taking shape.

And at such an inflection point, every company's choice will be magnified into a directional answer.

If MacMillan's 12 years must be defined, it is not "growth," but "consolidation."

He enabled Hologic to make the leap from volatility to stability, from uncertainty to predictability, transforming a company into a sustainably operational platform.

But the evolution of enterprises never stops at "stability."

When the industry enters a new cycle, stability itself may become a new constraint, and past advantages could turn into future boundaries.

Therefore, this departure is not essentially a personal leave, but a phase transition — from "holding on to a certain present" to "embracing an uncertain future."

The change of a company is a microcosm of an industry.

Many people will see this as a simple personnel change.

But if we take a higher perspective, we will find that this is actually a microcosm of the structural changes in the IVD industry.

When the logic of growth changes, when the logic of capital changes, when the dimensions of competition change, every move a company makes becomes more purposeful.

This step by Hologic is not the end, but the beginning.

It represents a trend: moving from "relying on a single growth curve" to "reconstructing a multi-dimensional capability system."

In the future IVD industry, it will no longer be about whose products are better, but whose systems are more complete.

It's no longer about who grows faster, but who can better navigate through cycles.

Only those enterprises that have completed the transition in advance are qualified to enter the next round of competition.